Abetimus: Difference between revisions
Content deleted Content added
Updating {{infobox_drug}} (changes to verified fields - updated 'ChemSpiderID_Ref') per Chem/infobox_drug validation (report errors or bugs) |
Anypodetos (talk | contribs) Drugbox additions; never marketed |
||
| Line 2: | Line 2: | ||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = 477237140 |
| verifiedrevid = 477237140 |
||
| drug_name = Abetimus sodium |
|||
| IUPAC_name = |
| IUPAC_name = |
||
| image = |
| image = |
||
<!-- Clinical data --> |
<!-- Clinical data --> |
||
| tradename = |
| tradename = Riquent |
||
| pregnancy_ |
| pregnancy_ |
||
| pregnancy_US = <!-- A / B / C / D / X --> |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
| Line 28: | Line 29: | ||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = none |
| ChemSpiderID = none |
||
| PubChemSubstance = 17397358 |
|||
| PubChem = |
|||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
| KEGG = D03204 |
|||
<!-- Chemical data --> |
<!-- Chemical data --> |
||
| chemical_formula = |
| chemical_formula = |
||
| C=1632 | H=1944 | N=610 | O=970 | P=156 | S=4 | Na=156 |
|||
| molecular_weight = |
| molecular_weight = |
||
}} |
}} |
||
'''Abetimus''' is an [[immunosuppressant]].<ref name="pmid12749759">{{cite journal |
'''Abetimus''' (trade name '''Riquent''') is an [[immunosuppressant]].<ref name="pmid12749759">{{cite journal |
||
| author = (not listed) | title = Abetimus: Abetimus sodium, LJP 394 |
| author = (not listed) | title = Abetimus: Abetimus sodium, LJP 394 |
||
| journal = BioDrugs | volume = 17 | issue = 3 | issn = 1173-8804 | publisher = Adis |
| journal = BioDrugs | volume = 17 | issue = 3 | issn = 1173-8804 | publisher = Adis |
||
| Line 43: | Line 46: | ||
| publisher = Informa | volume = 10 | issue = 1 | pages = 111–117 | issn = 1354-3784 |
| publisher = Informa | volume = 10 | issue = 1 | pages = 111–117 | issn = 1354-3784 |
||
| url = http://informahealthcare.com/doi/abs/10.1517/13543784.10.1.111%20 | pmid = 11116284 |
| url = http://informahealthcare.com/doi/abs/10.1517/13543784.10.1.111%20 | pmid = 11116284 |
||
| doi = 10.1517/13543784.10.1.111 }}</ref> It may also complex anti dsDNA antibodies together, therefore disabling them. This way |
| doi = 10.1517/13543784.10.1.111 }}</ref> It may also complex anti dsDNA antibodies together, therefore disabling them. This way abetimus was supposed to help treat [[systemic lupus erythematosus]] and specifically [[lupus nephritis]]. |
||
It was developed by [[La Jolla Pharmaceutical]], who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.<ref>{{cite web|url=https://www.drugs.com/history/riquent.html|title=Riquent Approval Status|publisher=[[Drugs.com]]|accessdate=7 January 2017}}</ref><ref>{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000733/wapp/Initial_authorisation/human_wapp_000074.jsp&mid=WC0b01ac058001d128|title=Riquent|publisher=[[European Medicines Agency]]|accessdate=7 January 2017}}</ref> |
|||
==References== |
==References== |
||
Revision as of 10:56, 7 January 2017
| Clinical data | |
|---|---|
| Trade names | Riquent |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| ChemSpider |
|
| KEGG | |
| Chemical and physical data | |
| Formula | C1632H1944N610Na156O970P156S4 |
| Molar mass | 54171.35 g·mol−1 |
  (what is this?) (verify) | |
Abetimus (trade name Riquent) is an immunosuppressant.[1] It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies.[2] It may also complex anti dsDNA antibodies together, therefore disabling them. This way abetimus was supposed to help treat systemic lupus erythematosus and specifically lupus nephritis.
It was developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.[3][4]
References
- ^ (not listed) (2003). "Abetimus: Abetimus sodium, LJP 394". BioDrugs. 17 (3). Adis: 212–215. doi:10.2165/00063030-200317030-00009. ISSN 1173-8804. PMID 12749759.
- ^ Wallace, Daniel J. (January 2001), "Clinical and pharmacological experience with LJP-394", Expert Opinion on Investigational Drugs, vol. 10, no. 1, Informa, pp. 111–117, doi:10.1517/13543784.10.1.111, ISSN 1354-3784, PMID 11116284, retrieved 2 April 2011
- ^ "Riquent Approval Status". Drugs.com. Retrieved 7 January 2017.
- ^ "Riquent". European Medicines Agency. Retrieved 7 January 2017.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |